Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrikefon vs sufentanil PCIA after minimally invasive distal pancreatectomy
ChiCTR2600124712Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hsk21542 in acute postoperative pain (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Area under the curve (AUC0–72h) of resting NRS pain score from 0 to 72 hours after surgery. Planned start May 2026; status: not yet recruiting.
02
Drugs
hsk21542
03
Conditions
acute postoperative pain
Beyond the preview
Go deeper on ChiCTR2600124712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124712.